{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-002674","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2022-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.487827+00:00","generated_at":"2026-06-24T13:23:18.847049+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entera Bio appoints Miranda Toledano CEO, Dana Yaacov-Garbeli CFO; former CEO Jamas departs with $411K","bullets":["Appointed Miranda Toledano as CEO effective July 15, 2022; she had served as CBO/CFO and director since 2018.","Toledano's amended employment: annual employer cost $380K, bonus eligibility 60% of base salary, option grant of 600K shares at $1.40.","Additional performance milestone options for 200K shares under long-term incentive.","Dana Yaacov-Garbeli promoted to CFO effective July 15; she was Israel-based CFO since June 2019.","Former CEO Spiros Jamas receives lump sum $411,666.67 (13 months salary) and extension of vested option exercise period for 492,832 shares for two years."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-002674","json":"https://secwatch.observer/filing/0001178913-22-002674.json","markdown":"https://secwatch.observer/filing/0001178913-22-002674.md","text":"https://secwatch.observer/filing/0001178913-22-002674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/0001178913-22-002674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/zk2228138.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T13:23:18.847049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a56e902f2d","claim":"Miranda J. Toledano was appointed as Chief Executive Officer at Entera Bio Ltd..","evidence_excerpt":"appointed Miranda J. Toledano, one of the Company’s existing directors and the Company’s Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy, as the Company’s Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/0001178913-22-002674-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c84f29c6d7","claim":"Dr. Spiros Jamas departed as Chief Executive Officer at Entera Bio Ltd..","evidence_excerpt":"separation from the Company of Dr. Spiros Jamas","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/0001178913-22-002674-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}